A federal appeals court has thrown out a Florida judge's ruling that threatened to gut one of the government's most powerful fraud-fighting tools, deciding Tuesday that private whistleblowers who sue on behalf of the United States are not acting as illegal stand-in federal officers. The unanimous three-judge panel's decision revives a Medicare fraud lawsuit against a Florida health care network and keeps the decades-old False Claims Act whistleblower mechanism alive nationwide, at least for now.
The case, Zafirov v. Florida Medical Associates LLC, was filed by Dr. Clarissa Zafirov, a board-certified family care physician who accused her former employer, doing business as VIPcare, of systematically submitting false Medicare Advantage diagnosis codes to inflate monthly risk-adjustment payments, according to Justia Law. As reported by Reuters, the 11th U.S. Circuit Court of Appeals disagreed with a 2024 ruling by U.S. District Judge Kathryn Kimball Mizelle, a Trump appointee, that had found the whistleblower provision improperly allows private citizens to wield executive branch authority.
Judge Mizelle's original decision made her the first federal judge to strike down the qui tam provisions of the Civil War-era False Claims Act, which allows private individuals to bring fraud claims on behalf of the United States even when the government declines to intervene. The 11th Circuit panel — which included Judges Elizabeth Branch and Robert Luck, both appointed by President Donald Trump, and Judge Federico Moreno, appointed by President George H.W. Bush — held that relators do not qualify as officers of the United States under Article II because they do not occupy a continuing position established by law. The Appointments Clause, the panel reasoned, requires presidential appointment or Senate confirmation only for continuous federal officers, whereas a relator's authority ends once a single lawsuit concludes.
A Fight Bigger Than One Florida Case
The ruling brings the 11th Circuit into line with the Fifth, Sixth, Ninth, and Tenth Circuits, all of which had already upheld the qui tam mechanism when the same Appointments Clause argument came before them, per the National Law Review. Judge Mizelle's 2024 decision had stood as an isolated departure from that established precedent, and she went on to reaffirm and expand her constitutional theory in a separate 2025 case, ruling that a relator holds a continuing office because that lawsuit survived the original whistleblower's death and passed to his estate's representative, according to Holland & Knight.
The U.S. Justice Department had urged the appeals court to uphold the whistleblower provision, arguing that federal officials retain sufficient control over whistleblower-led litigation to satisfy constitutional concerns, the article notes. Daniel Winik represented the United States for the Justice Department, while Tejinder Singh represented Dr. Zafirov. On the other side, attorney Kannon Shanmugam represented the Florida health care providers accused of defrauding the government, appearing for law firm Davis Polk. The U.S. Chamber of Commerce also participated in the hearing in support of medical organizations backing the defendants' position.
The Case Isn't Over Yet
Tuesday's decision does not end the legal fight. The panel vacated Judge Mizelle's ruling but sent the case back to her courtroom so she can evaluate the defendants' remaining constitutional arguments under Article II's Take Care Clause and Vesting Clause, according to the 11th U.S. Circuit Court of Appeals. Those clauses go to whether private whistleblowers unconstitutionally strip the president of executive control over civil law enforcement — a separate question the appellate panel left entirely unresolved.
Shanmugam acknowledged the case is far from finished, telling Reuters that the ruling addressed only one part of the defendants' constitutional challenge and that “we're assessing our options in light of today's ruling.” The case, numbered No. 24-13581, now returns to the trial court for further litigation on those remaining claims.
Why the Law Matters Financially
The False Claims Act whistleblower provision has been used to recover billions of dollars from fraud against the government, and the stakes explain why corporate defendants keep testing its constitutionality. Since the law was modernized in 1986 through legislation authored by Senator Chuck Grassley, the federal government has recovered more than $70 billion from fraudulent contractors and health care providers, according to the Office of U.S. Senator Chuck Grassley. In fiscal year 2023 alone, whistleblowers filed 712 qui tam lawsuits that generated over $2.3 billion of the $2.68 billion in total civil fraud recoveries the Justice Department recorded that year, per Greenberg Traurig LLP.
Under the law, whistleblowers receive 15% to 25% of proceeds when the government intervenes and helps litigate a case, or 25% to 30% when the government does not intervene and the relator pursues the claim alone. That financial incentive is precisely what conservative legal theorists have targeted for decades — objections dating back to 1989, when then-Assistant Attorney General William Barr authored an Office of Legal Counsel opinion calling the qui tam device an unconstitutional delegation of executive authority to what he termed “private bounty hunters,” according to Dinsmore & Shohl LLP.
Supreme Court Pressure Still Looms
The current wave of challenges traces back to a June 2023 Supreme Court decision, U.S. ex rel. Polansky v. Executive Health Resources, Inc., in which Justice Clarence Thomas wrote a solo dissent arguing that private relators wielding federal litigation authority without executive appointment inhabit a constitutional twilight zone. Justices Brett Kavanaugh and Amy Coney Barrett both signaled in concurrences that the high court should eventually address whether private relators unconstitutionally exercise executive power.
Corporate defendants have taken notice. Pharmaceutical giant Eli Lilly petitioned the Supreme Court in March seeking to strike down qui tam actions as unconstitutional, after facing a $183 million trebled False Claims Act judgment over Medicaid drug pricing disclosures. With three sitting justices already on record expressing interest in the question, Tuesday's ruling preserves the whistleblower mechanism for now, but it does little to settle the broader constitutional debate that appears increasingly likely to land before the Supreme Court itself.
